Journal
IMMUNOTHERAPY
Volume 7, Issue 6, Pages 611-619Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.15.35
Keywords
GM-CSF; HSV; immune therapy; injectable; melanoma; oncolytic; talimogene laherperepvec; T-VEC
Categories
Funding
- NIH [K12 CA 0906525]
- NATIONAL CANCER INSTITUTE [K12CA090625] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Melanoma often spreads to cutaneous or subcutaneous sites that are amenable to direct, intralesional injection. As such, developing effective injectable agents has been of considerable interest. Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for the treatment of advanced melanoma. Pre-clinical studies have shown that T-VEC preferentially infects melanoma cells and exerts antitumor activity through directly mediating cell death and by augmenting local and even distant immune responses. T-VEC has now been assessed in Phase II and III clinical trials and has demonstrated a tolerable side-effect profile and promising efficacy, showing an improved durable response rate and a trend toward superior overall survival compared to granulocyte-macrophage colony-stimulating factor. Despite these promising results, responses have been uncommon in patients with visceral metastases. T-VEC is currently being evaluated in combination with other immune therapies (ipilimumab and pembrolizumab) with early signs of activity. In this review, we discuss the preclinical rationale, the clinical experience, and future directions for T-VEC in advanced melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available